Series A cash for Brenus, GCTx, Nura among week’s VC highlights

The week’s series A rounds included French cancer vaccines play Brenus and iPSC programming company GC Therapeutics, while Belgium-based Tanai added seed capital from a new investment initiative at Novo Nordisk.

Brenus Pharma S.A. is moving toward first-in-human testing of a lead program from its STC platform, which is designed to mimic cancer cells’ resistance and escape mechanisms in the laboratory, and thwart tumor relapses. Around year-end, the company is aiming to start clinical testing of STC-1010 to treat unresectable, metastatic colorectal cancer resistant to immunotherapies, with future testing planned in other gastric cancers...